| DIRECT COMPETITOR COMPARISON | |
| ICCC | IDXX | PFE | MRK | Industry | | Market Cap: | 11.73M | 3.00B | 150.68B | 77.29B | 59.95M | | Employees: | 32 | 4,700 | 81,800 | 55,200 | 56 | | Qtrly Rev Growth (yoy): | 9.50% | 3.20% | -2.90% | 1.80% | 18.90% | | Revenue (ttm): | 4.72M | 1.00B | 45.82B | 23.37B | 12.73M | | Gross Margin (ttm): | 50.41% | 51.15% | 86.61% | 76.36% | 50.63% | | EBITDA (ttm): | -312.37K | 216.89M | 21.31B | 7.81B | -1.76M | | Oper Margins (ttm): | -15.23% | 16.69% | 37.42% | 26.63% | -19.80% | | Net Income (ttm): | -241.34K | 114.83M | 8.09B | 8.05B | N/A | | EPS (ttm): | -0.082 | 1.888 | 1.204 | 3.808 | N/A | | P/E (ttm): | N/A | 27.14 | 15.51 | 9.62 | 23.74 | | PEG (5 yr expected): | N/A | 1.43 | 6.03 | 2.21 | 1.33 | | P/S (ttm): | 2.52 | 3.00 | 3.30 | 3.32 | 3.00 |
|
| IDXX = IDEXX Laboratories Inc. | | PFE = Pfizer Inc. | | MRK = Merck & Co. Inc. | | Industry = Diagnostic Substances | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.895 | -1.05% | 57.59B | 12.41 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.612 | -0.27% | 13.77B | 15.93 | | Genzyme Corp. | GENZ | 50.865 | -0.83% | 13.50B | 29.00 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.73 | 0.41% | 42.05B | 18.07 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.69 | -0.69% | 9.04B | 1034.49 | | Teva Pharmaceutical Industries Limited | TEVA | 54.19 | 0.46% | 47.74B | 49.58 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.60 | -0.21% | 3.99B | 19.38 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.79 | 0.17% | 2.93B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.301 | -1.13% | 5.59B | 112.28 | | Pfizer Inc. | PFE | 18.6727 | -0.36% | 150.68B | 15.51 | | Johnson & Johnson | JNJ | 64.03 | 0.23% | 176.67B | 13.98 | | GlaxoSmithKline plc | GSK | 42.51 | 0.31% | 107.76B | 13.37 | | Sanofi-Aventis | SNY | 39.67 | -0.20% | 103.58B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 56.26 | 0.88% | 127.78B | 16.84 | | RHHBY.PK | 41.94 | 1.23% | N/A | N/A | | AstraZeneca plc | AZN | 45.99 | 0.13% | 66.69B | 9.23 | | Abbott Laboratories | ABT | 54.46 | 0.04% | 84.24B | 14.75 | | Bristol-Myers Squibb Co. | BMY | 24.98 | 0.85% | 49.48B | 12.92 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|